Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 8, pp. 1482-1486
Open Access | Times Cited: 216

Showing 26-50 of 216 citing articles:

Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds
Neeraj Choudhary, Sweta Bawari, Jack T. Burcher, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3980-3980
Open Access | Times Cited: 19
Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation
Ning Yang, Zhiya Fan, Shiyang Sun, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115857-115857
Closed Access | Times Cited: 19
Drug Delivery Strategies for the Treatment of Pancreatic Cancer
Oluwabukunmi Olajubutu, Omotola D. Ogundipe, Amusa S. Adebayo, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1318-1318
Open Access | Times Cited: 17
Research progress on non-protein-targeted drugs for cancer therapy
Yiwen Zhang, Lu Lu, Feifeng Song, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 16
Targeted therapeutic options in early and metastatic NSCLC-overview
Gabriella Gálffy, Éva Morócz, Réka Korompay, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
EGFR, the Lazarus target for precision oncology in glioblastoma
Benjamin Lin, Julia Ziebro, Erin Smithberger, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 12, pp. 2035-2062
Open Access | Times Cited: 26
Targeting KRAS in PDAC: A New Way to Cure It?
Qianyu He, Zuojia Liu, Jin Wang
Cancers (2022) Vol. 14, Iss. 20, pp. 4982-4982
Open Access | Times Cited: 26
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
Thomas Yul Avery, Natalie Köhler, Robert Zeiser, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 24
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
Kirsten McAulay, Alan Bilsland, Marta Bon
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1366-1366
Open Access | Times Cited: 22
A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer
Thomas Hofmarcher, Chiara Malmberg, Peter Lindgren
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 14
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Rodrigo Entrialgo‐Cadierno, Cristina Cueto‐Ureña, Connor Welch, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 13
A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor
Yan Lv, Zixuan Yang, Yiming Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2487-2511
Closed Access | Times Cited: 5
Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis
Tian Tian, Yanying Li, Juan Li, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 4, pp. 861-874
Open Access | Times Cited: 5
Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
Mi-Ju Park, Jung Ho Han, Shibo Wei, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 807-807
Open Access | Times Cited: 4
Elucidating the therapeutic potential of indazole derivative bindarit against K-ras receptor: An in-silico analysis using molecular dynamics exploration
Parmar Keshri Nandan, Sivaraman Jayanthi
Biochemistry and Biophysics Reports (2025) Vol. 41, pp. 101913-101913
Closed Access
Targeting KRAS G12C and G12S Mutations in Lung Cancer: In Silico Drug Repurposing and Antiproliferative Assessment on A549 Cells
Mansour S. Alturki, Nada Tawfeeq, Amal Alissa, et al.
Informatics in Medicine Unlocked (2025), pp. 101612-101612
Open Access
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib
Jingjing Xiang, Liangliang Cai, Qin Wang, et al.
Frontiers in Chemistry (2025) Vol. 12
Open Access
Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development
Han Koo, Kyung Chan Park, Hyun Ahm Sohn, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Kras Ctdna Detection in Patients with Resectable Lung Adenocarcinoma
Meghan L. De Meo, Joseph Seitlinger, Roni Rayes, et al.
(2025)
Closed Access
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China
Liyuan Wu, Wei Rao, Lei Guo, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 2
Open Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective
Vimal H. Prajapati, Ankit Kumar Singh, Adarsh Kumar, et al.
RSC Medicinal Chemistry (2025)
Closed Access

Scroll to top